All In Biotech

NDA 021246 · Roche

Tamiflu

Oseltamivir Phosphate · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Dec 14, 2000

Approved uses

6

Original approval plus efficacy supplements

Registered trials

156

44 Phase 3, 10 recruiting

FAERS reports

18,140

11,193 serious, 1,814 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2025.

TAMIFLU is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza TAMIFLU is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza TAMIFLU is indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use TAMIFLU is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU [see Microbiology (12.4) ] . TAMIFLU is not recommended for patients with end-stage renal disease not undergoing dialysis [see Dosage and Administration (2.4) and Use in Specific Populations (8.6) ].

Mechanism: Oseltamivir is an antiviral drug with activity against influenza virus [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TAMIFLU · OSELTAMIVIR PHOSPHATE EQ 12MG BASE/ML · FOR SUSPENSION, ORAL · Discontinued
  • TAMIFLU · OSELTAMIVIR PHOSPHATE EQ 6MG BASE/ML · FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Oseltamivir" as an intervention, any sponsor and status, largest first.

All 156 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting1,886
  • nausea1,364
  • no adverse event1,058
  • influenza963
  • abnormal behaviour927
  • diarrhoea867
  • dyspnoea863
  • hallucination827
  • pyrexia746
  • headache678
  • drug ineffective648
  • pneumonia644

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004153
2005393
2006278
2007546
2008351
20091,569
20101,311
2011477
2012518
2013550
2014475
20151,361
20161,136
20171,867
20181,599
20191,157
20201,013
2021405
2022380
2023525
20241,174
2025556
2026345

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tamiflu (Oseltamivir Phosphate)

2024 spending

$56K

Beneficiaries

528

593 claims

Per beneficiary

$107

$9.65 per unit

View as table
YearSpending
2020$254,695
2021$34,177
2022$274,839
2023$67,191
2024$56,462

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 323 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.